

CORPORATE OVERVIEW

CardieX is an ASX listed public company with operations in medical technology, wearable devices, and telehealth.

Our core medical business (AtCor Medical) develops, markets, and distributes medical technologies that measure patient risk for hypertension, cardiovascular disease (CVD), and other related vascular disorders. Our wearable and “smart device” division (CardieX

Labs in partnership with Blumio), develops non-invasive wearable technologies that identify patient risk profiles for hypertension, CVD, and related disorders.


Our telehealth group (inHealth) develops and provides clinically based health coaching and management to health insurance networks, private practice, and medical device companies.

BUSINESS OVERVIEW

We provide digital and device-based solutions for large-scale population health disorders with significant market scale.

- Current focus is **cardiovascular disease (CVD) and heart health** - the #1 cause of premature death globally.
- Our long-term future lies in developing large-scale health technologies in other significant global wellness markets (e.g. obesity, orthopedic health, diabetes management, urology).

We provide investment exposure to 3 of the fastest growing global healthcare market opportunities.



CORPORATE & FINANCIAL INFORMATION

SECURITIES ON ISSUE:

695,435,563 **23,310,000**

TOTAL SHARES (ASX.CDX) EMPLOYEE OPTIONS

97,497,625 **36,000,000**

TOTAL OPTIONS (ASX.CDX) PERFORMANCE RIGHTS
(\$0.05 Ex Price)

STOCK LISTING:

CDX

ASX: AUSTRALIAN
SECURITIES EXCHANGE

HEAD OFFICE:

CardieX, Limited
303/15 Lime St
Sydney NSW 2000
Australia

AUDITORS:

BDO



MAJOR STOCK HOLDERS (AS OF MAY, 2019):

RANK	NAME	NUMBER OF SHARES	PERCENTAGES
1	C2 VENTURES PTY LIMITED	137,616,769	19.79%
2	MR PAUL COZZI	25,425,114	3.66%
3	CITICORP NOMINEES PTY LIMITED	16,239,028	2.34%
4	CB CO PTY LTD	15,470,000	2.22%
5	MR PAUL JOSEPH COZZI	13,973,617	2.01%
6	CAMPBELL KITCHENER HUME & ASSOCIATES PTY LTD	11,570,923	1.66%
7	DRUMNADROCHIT FUTURES PTY LTD	10,068,574	1.45%
8	MRS JANE GREENSLADE	9,996,504	1.44%
9	AUSTRALIAN EXECUTOR TRUSTEES LIMITED	8,400,000	1.21%
10	CPO SUPERANNUATION FUND PTY LTD	7,330,000	1.05%
Total Top 10		256,090,529	36.8%
Balance		439,345,034	63.2%
Total		695,435,563	100.0%

Average Daily Volume (1/7/18 - 24/5/19): 3,178,201

GROUP FINANCIALS

REVENUE:

\$4,006,091 FY18**\$1,987,846** HY19C2 VENTURES PTY
LTD INVESTMENT
TO DATE**\$4,000,000**

(Niall Cairns & Craig Cooper)

CASH:

\$2,736,517 FY18**\$4,735,364** HY19

MARKET CAP:

\$25,035,680

24/05/19

BOARD OF DIRECTORS

NIALL CAIRNS

Non-Executive Chairman

CRAIG COOPER

Executive Director, CEO,
and Managing Director

R. KING NELSON

Non-Executive Director

KEY EXECUTIVES

CRAIG COOPER

Executive Director, CEO,
and Managing Director

JARROD WHITE

Chief Financial Officer

ZIHAN LIN

VP of Corporate
Development

CHRIS DAX

VP of Operations

DOUG KURSCHINSKI

VP & Global Head of Sales,
AtCor Medical

RHONDA WELCH

VP of Global Marketing

LAWRENCE CHAN

Director of Product
Development

VALUE PROPOSITION

CardieX has three operating divisions focused on developing and marketing solutions and technologies for large-scale population health disorders.

“ Our core mission is to develop a significant and valuable healthcare ecosystem of complementary and strategic products and services - and to provide smarter tools to help identify, diagnose, and treat patients with confidence. ”

MEDICAL DEVICES

AtCor Medical and its proprietary XCEL system is the world leader in noninvasive measurement of arterial stiffness and central blood pressure (cBP) which is considered essential for the management of hypertension and related cardiovascular disorders.



WEARABLE TECHNOLOGIES

CardieX Labs has a 50/50 joint venture partnership with Silicon Valley-based Blumio, for the development of a radar-based blood pressure sensor incorporating CardieX cBP technology. CardieX is also partnering with leading global wearable and smart device companies to incorporate AtCor's sensor and diagnostic technology into next generation wearable diagnostic technologies.



TELEHEALTH SOLUTIONS

inHealth Medical Services, is a leading provider of telehealth solutions in the US, providing digital, e-commerce and mobile tools for patients to connect online with health coaches as part of a patient care program. inHealth's patient care programs are based on long-term clinical trials that demonstrate superior patient outcomes through the use of telehealth coaching services. inHealth has partnerships with some of the leading healthcare institutions in the USA including Anthem, American Well, and Kaiser Permanente.



Our health solutions and IP have the potential to disrupt multiple multi-billion dollar markets in preventative diagnostics, patient management, wearables, and consumer/digital health.

KEY PARTNERSHIPS



INVESTOR RELATIONS

SHARE REGISTRY

For questions about your shareholding please contact the share registry:

**Computershare,
Investor Services**

Level 3
60 Carrington Street
Sydney NSW 2000
Australia
Tel: +61 2 8234 5000

www.computershare.com/au

GENERAL INVESTOR ENQUIRIES

Jarrold White

Company Secretary
Suite 303, 15 Lime Street
Sydney NSW 2000
Australia
Tel: +61 2 9874 8761

Email: jwhite@cardiex.com

FOR MEDIA & INVESTOR RELATIONS

Peter Taylor

NWR Communications
Tel: + 61 412 036 231

Email: peter@nwrcommunications.com.au